October 13 (Thu), 12:10-13:00, Rm. 300

The healthy immune system employs a series of checkpoints in order to maintain self-tolerance or prevent collateral tissue damage during an immune response.

Immune checkpoint ligands are often up-regulated in cancer cells as a means to evade immune detection. Activating antitumor immunity through the blockade of immune checkpoint proteins has become a promising therapeutic strategy for the treatment of cancer.

Fluorescent multiplex immunohistochemistry (mIHC) is a method that enables simultaneous detection of multiple (2-6 or more) proteins of interest in formalin-fixed paraffin-embedded (FFPE) tissue. mIHC allows the simultaneous detection of multiple (>6) targets of interest in a species/isotype independent manner while providing ample signal amplification. Monoclonal antibodies developed and validated by CST can enable co-detection and spatial characterization of important immune checkpoint control proteins using mIHC.